医学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
2019年冠状病毒病(COVID-19)
重新调整用途
Sars病毒
2019-20冠状病毒爆发
药物重新定位
冠状病毒
重症监护医学
病毒学
倍他科诺病毒
临床试验
药品
组织向性
病毒
向性
药理学
爆发
病理
生态学
疾病
传染病(医学专业)
生物
作者
Anna Mary Jose,Pramita Muntode
标识
DOI:10.5005/japi-11001-0140
摘要
A total number of 1,524,161 active cases, 92,941 deaths, and 213 countries have been affected worldwide by COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as of 11th April 2020. Much can be attributed to the virus’ structural protein, S protein, which determines its host range and tissue tropism and aids its rapid spread. This review aims to summarize numerous researches carried out with respect to the complex and resistant structure of SARS-CoV-2 in addition to the researches performed on various antivirals on the basis of drug repurposing, to aid in better understanding for future researches, clinical trials, and treatment protocols
科研通智能强力驱动
Strongly Powered by AbleSci AI